Torbjörn Gräslund

2.3k total citations
67 papers, 1.7k citations indexed

About

Torbjörn Gräslund is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Torbjörn Gräslund has authored 67 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Radiology, Nuclear Medicine and Imaging, 42 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in Torbjörn Gräslund's work include Monoclonal and Polyclonal Antibodies Research (51 papers), Glycosylation and Glycoproteins Research (21 papers) and HER2/EGFR in Cancer Research (18 papers). Torbjörn Gräslund is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (51 papers), Glycosylation and Glycoproteins Research (21 papers) and HER2/EGFR in Cancer Research (18 papers). Torbjörn Gräslund collaborates with scholars based in Sweden, Russia and Denmark. Torbjörn Gräslund's co-authors include Per‐Åke Nygren, Vladimir Tolmachev, Anna Orlova, Fredrik Y. Frejd, John Löfblom, Sophia Hober, Stefan Ståhl, Amelie Eriksson Karlström, Mathias Uhlén and Camilla Hofström and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and ACS Nano.

In The Last Decade

Torbjörn Gräslund

66 papers receiving 1.7k citations

Peers

Countries citing papers authored by Torbjörn Gräslund

Since Specialization

Citations

This map shows the geographic impact of Torbjörn Gräslund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torbjörn Gräslund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torbjörn Gräslund more than expected).

Fields of papers citing papers by Torbjörn Gräslund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Torbjörn Gräslund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torbjörn Gräslund. The network helps show where Torbjörn Gräslund may publish in the future.

Co-authorship network of co-authors of Torbjörn Gräslund

This figure shows the co-authorship network connecting the top 25 collaborators of Torbjörn Gräslund. A scholar is included among the top collaborators of Torbjörn Gräslund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Torbjörn Gräslund. Torbjörn Gräslund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture 2025 ·International Journal of Molecular Sciences ·Vladimir Tolmachev, Anzhelika Vorobyeva, (unknown), Javad Garousi, (unknown), Torbjörn Gräslund, (unknown), Alexey Schulga, Е. В. Коновалова, Anna Orlova, Sergey M. Deyev, Maryam Oroujeni	1
2	Bioengineered Nanomedicines Targeting the Intestinal Fc Receptor Achieve the Improved Glucoregulatory Effect of Semaglutide in a Type 2 Diabetic Mice Model 2024 ·ACS Nano ·Soraia Pinto, Juliana Santos Rosa Viegas, (unknown), Catarina Pacheco, (unknown), Stephen T. Buckley, Javad Garousi, Torbjörn Gräslund, Hélder A. Santos, Bruno Sarmento	9
3	Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts 2024 ·ACS Pharmacology & Translational Science ·Jie Zhang, Sara S. Rinne, (unknown), (unknown), E. Bjorklund, Ayman Abouzayed, Stefan Ståhl, John Löfblom, Anna Orlova, Torbjörn Gräslund, Anzhelika Vorobyeva	2
4	Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs 2023 ·Journal of Controlled Release ·(unknown), Tianqi Xu, (unknown), Jie Zhang, (unknown), (unknown), М. В. Белоусов, (unknown), Maryam Oroujeni, Anna Orlova, Vladimir Tolmachev, Torbjörn Gräslund, Anzhelika Vorobyeva	11
5	Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart 2022 ·Pharmaceutics ·Javad Garousi, Tianqi Xu, (unknown), Olga Vorontsova, Sophia Hober, Anna Orlova, Vladimir Tolmachev, Torbjörn Gräslund, Anzhelika Vorobyeva	3
6	Proof-of-Concept of Continuous Transfection for Adeno-Associated Virus Production in Microcarrier-Based Culture 2022 ·Processes ·Brian Ladd, (unknown), Mats Lundgren, Torbjörn Gräslund, Véronique Chotteau	4
7	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules 2022 ·Biomedicines ·Sara S. Rinne, (unknown), (unknown), Ayman Abouzayed, (unknown), Anzhelika Vorobyeva, John Löfblom, Stefan Ståhl, Anna Orlova, Torbjörn Gräslund	5
8	Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer 2022 ·International Journal of Molecular Sciences ·(unknown), Evgenii Plotnikov, (unknown), (unknown), (unknown), (unknown), Roman Zelchan, Alexey Schulga, Е. В. Коновалова, Anzhelika Vorobyeva, Javad Garousi, Torbjörn Gräslund, М. В. Белоусов, Vladimir Tolmachev, Sergey M. Deyev	4
9	Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2 2022 ·Pharmaceutics ·Tianqi Xu, Jie Zhang, Maryam Oroujeni, (unknown), (unknown), М. В. Белоусов, Anna Orlova, Vladimir Tolmachev, Anzhelika Vorobyeva, Torbjörn Gräslund	7
10	Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT 2022 ·Pharmaceutics ·(unknown), (unknown), Tianqi Xu, (unknown), Anna Orlova, Maryam Oroujeni, Sara S. Rinne, Vladimir Tolmachev, Anzhelika Vorobyeva, Torbjörn Gräslund	7
11	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model 2021 ·Cancers ·Tianqi Xu, Anzhelika Vorobyeva, Alexey Schulga, Е. В. Коновалова, Olga Vorontsova, (unknown), Torbjörn Gräslund, Л. А. Таширева, Anna Orlova, Vladimir Tolmachev, Sergey M. Deyev	11
12	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy 2021 ·Pharmaceutics ·(unknown), Tianqi Xu, (unknown), Maryam Oroujeni, Jie Zhang, Anzhelika Vorobyeva, Olga Vorontsova, С. В. Вторушин, Vladimir Tolmachev, Torbjörn Gräslund, Anna Orlova	11
13	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein 2021 ·Pharmaceutics ·Javad Garousi, (unknown), (unknown), Tianqi Xu, Anzhelika Vorobyeva, Maryam Oroujeni, Anna Orlova, Sophia Hober, Torbjörn Gräslund, Vladimir Tolmachev	8
14	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution 2021 ·Pharmaceutics ·(unknown), Tianqi Xu, Jie Zhang, Vladimir Tolmachev, Maryam Oroujeni, Anna Orlova, Torbjörn Gräslund, Anzhelika Vorobyeva	14
15	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1 2021 ·Cancers ·Sergey M. Deyev, Tianqi Xu, (unknown), Alexey Schulga, Е. В. Коновалова, Javad Garousi, Sara S. Rinne, (unknown), (unknown), Torbjörn Gräslund, Anna Orlova, Vladimir Tolmachev, Anzhelika Vorobyeva	12
16	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model 2020 ·Cancers ·Tianqi Xu, (unknown), Anzhelika Vorobyeva, Maryam Oroujeni, Anna Orlova, Vladimir Tolmachev, Torbjörn Gräslund	25
17	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution 2020 ·Pharmaceutics ·(unknown), (unknown), (unknown), Sarah Lindbo, Hao Liu, Javad Garousi, Tianqi Xu, Anna Orlova, Vladimir Tolmachev, Sophia Hober, Torbjörn Gräslund	7
18	An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation 2019 ·PLoS ONE ·(unknown), (unknown), Gunnar Norstedt, Torbjörn Gräslund	8
19	In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor 2018 ·Scientific Reports ·(unknown), (unknown), Fredrik Y. Frejd, Ingmarie Höidén‐Guthenberg, Torbjörn Gräslund	37
20	An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein 2014 ·Proceedings of the National Academy of Sciences ·(unknown), Malin Lindborg, Ingmarie Höidén‐Guthenberg, Heiko Bönisch, (unknown), Fredrik Y. Frejd, Lars Abrahmsén, Caroline Ekblad, John Löfblom, Mathias Uhlén, Torbjörn Gräslund	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact